FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00656 FOSUN INTL

Market Closed 12-12 16:08:09

4.870

+0.120

+2.53%

High4.880	Low4.730	Vol4.60M
Open4.790	D1 Closing4.750	Amplitude3.16%
Mkt Cap39.77B	Tradable Cap39.77B	Total Shares8.17B
T/O22.27M	T/O Rate0.06%	Tradable Shares8.17B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00656","market":"HK","secType":"STK","nameCN":"FOSUN INTL","latestPrice":4.87,"timestamp":1765526889002,"preClose":4.75,"halted":0,"volume":4604798,"delay":0,"floatShares":8167000000,"shares":8167000000,"eps":-0.5899644092910373,"marketStatus":"Market Closed","change":0.12,"latestTime":"12-12 16:08:09","open":4.79,"high":4.88,"low":4.73,"amount":22273798,"amplitude":0.031579,"askPrice":4.87,"askSize":33500,"bidPrice":4.86,"bidSize":23500,"shortable":3,"etf":0,"ttmEps":-0.5984814047637569,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":7,"adr":0,"listingDate":1184515200000,"exchange":"SEHK","adjPreClose":4.75,"dividendRate":0.00425,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":1.3909602166844763,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00656/tweets","defaultTab":"tweets","newsList":[{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","AZN.UK","MTSR","OPK","02105","LU1323610961.USD","AMGN","LU0256863902.USD","IE00BN8TJ469.HKD","LU1720051017.SGD","IE0002141913.USD","IE00BK4W5M84.HKD","MRK","LU0345777147.USD","00656","LU1061106388.HKD","LU1035775433.USD","03165","SGXZ99366536.SGD","LU1989772840.SGD","LU0106261372.USD","SG9999014906.USD","SRRK","LU0964806797.USD","03692","IE0005OL40V9.USD","600196","LU1989771016.USD","BK0028","LLY","SG9999013999.USD","LU0499090636.EUR","BK4566","LU0823434583.USD","BK0187","LU0211328371.USD","SG9999002224.SGD","IE00B4JS1V06.HKD","LU0130517989.USD","IE00BJJMRX11.SGD","LU2106854487.HKD","ALT","BK0188","GPCR","SG9999015986.USD","03933","LU1003077747.HKD","IE00BJLML261.HKD","LU0306806265.USD"],"gpt_icon":1},{"id":"2590503933","title":"Shanghai Fosun Pharmaceutical Subsidiary Wins Approval for Ketoprofen Patch Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503933","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503933?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:36","pubTimestamp":1765539382,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Subsidiary Zhaohui Pharma Receives Approval for Ketoprofen Patch Phase III Clinical Trial. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLc6cwnx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0187","BK0196","BK1230","BK0028","BK0183","BK0188","BK0060","BK0012","00656","BK0096","600196","BK0239"],"gpt_icon":0},{"id":"2590719945","title":"Henlius Biotech's Serplulimab NDA for Gastric Cancer Combo Granted Priority Review by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590719945","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590719945?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:48","pubTimestamp":1765529285,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its New Drug Application  for HANSIZHUANG  in combination with chemotherapy for neo-/adjuvant treatment of gastric cancer has been accepted by the National Medical Products Administration  of China and has been granted priority review. This regulatory milestone follows the achievement of the primary endpoint in a Phase 3 clinical trial in mainland China. No other organizations were mentioned as recipients of this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL1YbQhN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","02696","BK1161","HK0000165453.HKD","BK1230"],"gpt_icon":0},{"id":"2590311384","title":"Shanghai Henlius Biotech Secures NMPA Approval for Phase 2/3 Trials of HLX22 and HLX87 in HER2-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311384","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590311384?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:15","pubTimestamp":1765271717,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that the National Medical Products Administration has approved applications for Phase 2/3 clinical trials of HLX22  in combination with HLX87  for the first-line treatment and neoadjuvant treatment of HER2-positive breast cancer. As of the announcement date, no similar combination has been approved for marketing globally. The approval marks a significant step forward in the company's oncology pipeline, but Henlius cautioned that successful development and commercialization of HLX22 and HLX87 cannot be guaranteed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service opera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL1L7tPm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1230","HK0000165453.HKD","02696","00656"],"gpt_icon":0},{"id":"2589355863","title":"Sisram Medical Announces Board and CEO Changes Effective January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355863","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355863?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:24","pubTimestamp":1765200246,"startTime":"0","endTime":"0","summary":"Sisram Medical Ltd. has announced changes to its management and board, effective January 1, 2026. Yi Liu, Lior Moshe Dayan, and Jiahong Li serve as executive directors, while Yifang Wu and Rongli Feng are non-executive directors. The board also includes Heung Sang Addy Fong, Chi Fung Leo Chan, Jenny Chen, and Kai Yu Kenneth Liu as independent non-executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL6z3QLr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1100","01696","BK1593","00656","BK1230"],"gpt_icon":0},{"id":"2589384401","title":"BNP Paribas increases stake in Belgium's largest insurer in $3.5 billion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2589384401","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589384401?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:44","pubTimestamp":1765176254,"startTime":"0","endTime":"0","summary":"UPDATE 2-BNP Paribas increases stake in Belgium's largest insurer in $3.5 billion dealBNP Paribas to increase stake in Ageas to 22.5%Ageas gains full control of AG InsuranceDeal includes renewed partn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL8N3XE06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2589037871","title":"Shanghai Henlius Biotech's FUTUONING Added to China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589037871","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589037871?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:25","pubTimestamp":1765103102,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its product FUTUONING  has been included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance  for 2025 in mainland China. The approval covers the use of FUTUONING in combination with Fulvestrant for the treatment of adult patients with hormone receptor positive and HER2 negative recurrent or metastatic breast cancer who have experienced disease progression after prior endocrine therapy. The updated NRDL will take effect from January 1, 2026, increasing patient access to FUTUONING and supporting the company's marketing and sales efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL2mHPQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","02696","HK0000165453.HKD","BK1161","00656"],"gpt_icon":0},{"id":"2588216500","title":"Does Fosun International’s Streamlining Strategy Make Its Low Valuation Look More Appealing in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588216500","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588216500?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:23","pubTimestamp":1764771816,"startTime":"0","endTime":"0","summary":"Wondering if Fosun International at HK$4.97 is quietly turning into a value opportunity, or just another value trap in Hong Kong stocks.\nThe share price is up 0.6% over the last week, 1.2% over the past month, and 12.7% year to date, yet anyone who has held for 3 or 5 years is still looking at -16.2% and -51.5% respectively.\nRecent headlines have focused on Fosun International streamlining its portfolio and deleveraging its balance sheet, as the group continues to refocus on core businesses...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/does-fosun-internationals-streamlining-strategy-make-its-low","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/does-fosun-internationals-streamlining-strategy-make-its-low","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","00656","BK1230"],"gpt_icon":0},{"id":"2588044653","title":"Shanghai Henlius Biotech Inc. Announces Date for 2025 Fourth Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044653?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:06","pubTimestamp":1764770763,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. has scheduled its 2025 Fourth Extraordinary General Meeting for 31 December 2025. The meeting will be held at the Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, PRC. Shareholders will have the opportunity to vote on the resolutions as set out in the meeting notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL92cp7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656","BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2588041759","title":"Shareholders to Vote on Renewal of Sinopharm Distribution Collaboration at Shanghai Henlius Biotech Inc. EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041759","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041759?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:57","pubTimestamp":1764770263,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. will hold an Extraordinary General Meeting on December 31, 2025, where shareholders will vote on the renewal of the Sinopharm distribution collaboration, a continuing connected transaction. The Independent Board Committee has issued a recommendation regarding the proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL1C0xBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK1161","BK1230","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2588204114","title":"Shanghai Henlius Biotech Partners with Avanc Pharma for Fovinaciclib Citrate Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2588204114","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588204114?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:48","pubTimestamp":1764769683,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. has entered into collaboration agreements with Avanc Pharma for the commercialisation of fovinaciclib citrate capsules. Under the terms of the agreements signed on December 3, 2025, Avanc Pharma will grant Henlius an exclusive license to commercialise the licensed product in designated areas and channels within China. The partnership follows a prior memorandum of cooperation and sets out arrangements for supply and commercialisation services, with Henlius handling distribution in regions where Avanc Pharma is permitted to sell the product under local policies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL4h08B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1161","02696","BK1230","00656"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03680","03681","06060","BK1574","BK1604","LU0384037296.USD","IE00BZ08YT58.USD","LU1188198961.HKD","LU0370786039.SGD","02411","LU0329678337.USD","BK1228","80992","BK1577","LU0072462343.USD","LU0359201612.USD","LU0054450605.USD","IE00B031J352.USD","02889","LU2045819591.USD","02190","01739","LU2242644610.SGD","01640","LU0082770016.SGD","02167","SG9999015945.SGD","01880","BK1100","BK1531","BK1154","BK1230","01448","BK1528","03896","BK1520","09996","LU0620787316.HKD","02268","BK1147","01833","LU1868837565.USD","BK1161","09636","LU0348735423.USD","LU0880133367.SGD","BK1141","LU0516423174.USD","BK1171","SG9999002950.SGD","02460","02420","LU1303224171.USD","LU0327786744.USD","LU0261950470.USD","LU1366334651.USD","LU0261947096.USD","02100","01809","LU1522347837.USD","06058","LU0516423091.SGD","LU0469268626.HKD","BK1527","06862","LU1328615791.USD","02670","LU1956131251.USD","BK1559","BK1227","BK1191","BK1571","00136","BK1140","BK1150","BK1144","IE00BQXX3F31.USD","SG9999003461.SGD","LU0455707207.USD","LU2153591404.USD","BK1522","LU0543330566.HKD","LU0289961442.SGD","HK0000500386.USD","02020","02858","02382","LU0048597586.USD","LU0819121731.USD","BK1618","LU2008162690.USD","00855","LU0531970944.HKD","LU1224709979.USD","86618","LU0211977185.USD","BK1222","06613","LU0084288322.USD","00512","LU0856984785.SGD","BK1197","LU0588545730.USD","09985","BK1600","BK1095","LU0541502299.USD","BK1124","LU0348827113.USD","LU0605514214.HKD","02551","SG9999015952.SGD","09699","SG9999001903.USD","BK1526","03939","02419","BK1160","BK1597","BK1610","BK1594","LU0049112450.USD","LU1282649067.USD","02250","BK1539","BK1247","SG9999000418.SGD","BK1151","02552","01735","LU0828237510.HKD","01969","01405","IE00BQXX3D17.EUR","02431","LU1720050803.USD","LU0043850808.USD","BYDDY","00798","BK1184","LU0499858602.USD","LU0828238088.HKD","BK1502","06855","HK0000165453.HKD","LU2298064838.USD","LU0140636845.USD","LU1508157978.USD","IE00BZ08YS42.EUR","LU0348767384.USD","02598","02392","02400","06618","LU0417516902.SGD","SG9999001093.SGD","06963","BK1582","BK1194","LU3063872942.SGD","00451","IE00B5MMRT66.SGD","LU0823426480.USD","BK1170","IE00B031HY20.USD","01818","06913","BK1544","IE00BZ08YR35.GBP","LU1861214812.USD","09959","LU1226287792.SGD","02013","LU0456827905.SGD","09690","06919","BK1557","BK1619","01070","02506","06677","02650","LU0345775950.USD","LU0572944931.SGD","LU0865486749.SGD","02158","LU1282649810.SGD","BK1564","LU2097828805.USD","03658","00267","SG9999000475.SGD","LU2449936058.SGD","02018","LU0039217434.USD","LU0871576103.HKD","IE0034224299.USD","06683","LU0052750758.USD","LU0516422440.USD","LU1039395188.USD","LU0326950275.SGD","LU0516422952.EUR","BK1512","LU0164872284.USD","LU2039709279.SGD","LU0572940350.SGD","02273","LU0417516571.SGD","02451","BK1110","LU0823397285.USD","BK1148","LU0868486357.SGD","LU2097828631.EUR","LU0011963245.USD","IE0003851619.USD","00992","LU1969619763.USD","03738","BK1220","BK1595","LU1008478684.HKD","09660","IE0008369823.USD","BK1589","LU0261950983.USD","LU1939255532.USD","LU1048588211.SGD","02556","00300","LU0823397103.USD","LU1974910355.USD","LU0244354667.USD","03998","82331","BK1592","02616","LU1226287875.USD","02298","IE0003795394.USD","LU0345776255.USD","06657","BK1591","80020","LU1981816686.USD","SG9999006597.SGD","00460","02142","BK1117","06160","BK1590","01911","SG9999006514.SGD","01877","BK1550","LU0791591158.USD","LU1267930227.SGD","LU0516422366.SGD","LU2543165471.USD","06138","LU2778985437.USD","01519","06988","BK1158","BK1224","06069","06086","IE00B8L5B284.USD","00826","BK1125","01318","LU1102505929.USD","06100","01440","LU0819123356.HKD","BK1500","02157","LU0143863784.USD","LU0315178854.USD","BK1116","LU1497733557.USD","00861","01333","02627","09927","81211","BK1143","BK1134","09990","BK1233","09678","LU1719994722.HKD","LU2023250504.SGD","BK1530","BK1596","LU0359202008.SGD","BK1111","SG9999015978.USD","02276","BK1096","BK1119","02105","LU0594300419.USD","LU1880383366.USD","LU0499858438.USD","LU1226287529.USD","LU0634319403.HKD","LNVGY","LU0310800965.SGD","LU0540923850.HKD","LU0737861699.HKD","BK1167","BK1578","BK1519","BK1566","LU0531971595.HKD","LU0289739343.SGD","01783","HK0000252160.HKD","LU0251144936.SGD","06609","LU1960683339.HKD","02533","02380","LU0259732245.USD","LU1861219969.SGD","BK1137","ANPDY","02696","01773","06821","02565","02228","03396","BK1579","LU0823038988.USD","LU2153592121.USD","LU1868838027.USD","LU1226288253.USD","BK1139","LU0348805143.USD","LU1152091754.HKD","LU1808992512.USD","09961","00777","00656","LU1481107354.HKD","BK1575","LU0254981946.USD","00875","02469","LU0431992006.USD","02150","BK1607","LU0348783233.USD","LU2424517915.HKD","LU1880383440.USD","BK1178","SG9999011746.SGD","00384","01471","LU1152091168.USD","BK1193","LU0314109678.HKD","BK1216","SG9999001226.SGD","01939","BK1553","00666","00999","LU1831875114.USD","02498","LU0594300179.USD","BK1225","IE00BYV24P56.USD","BK1588","BK1209","LU0287142896.SGD","02511","01093","01681","02488","BK1609","BK1229","LU0067412154.USD","BK1560","LU0173614495.USD","HK0000306685.HKD","LU0307460666.USD","03677","LU0823414551.USD","06633","BK1169","BK1136","LU0505663152.USD","LU1813983027.USD","03800","IE0009570106.USD","HK0000320264.USD","LU0823437842.USD","00363","BK1258","LU0417516738.SGD","BK1555","BK1552","LU1951186391.HKD","LU2399975544.HKD","BK1142","BK1540","09992","LU0315179316.USD","LU2106854487.HKD","LU0052756011.USD","LU1211504680.USD","01600","LU0561508036.HKD","LU1634259557.SGD","LU0449509016.USD","LU0702159699.USD","02315","03709","BK1608","LU1961090484.USD","IE0032431581.USD","01907","LU0762540952.USD","LU0791590937.USD","LU2357125470.USD","09923","01952","02155","BK1175","IE00B0169L03.USD","LU0175139822.USD","LU0329678170.USD","BK1164","LNNGY","LU0511384066.AUD","LU0463099449.HKD","01211","BK1549","BK1587","LU2476274308.USD","82020","LU0456846285.SGD","01384","SG9999000459.SGD","00302","02629","BK1523","LU0107464264.USD","BK1114","HYDD.SI","LU0082770016.USD","002594","LU0501845795.SGD","LU0831093199.SGD","LU2097828714.EUR","09878","BK1616","LU1102505762.USD","00884","06608","00020","03650","BK1518","LU1251922891.USD","LU2097828474.EUR","02567","BK1253","BK1168","LU0541501648.USD","LU0274383008.USD","LU0165289439.USD","09911","03145","LU0348825331.USD","06168","01164","00135","02279","LU2663582299.SGD","LU0143863198.USD","09890","LU0588545904.SGD","BK1155","02121","BK1198","LU0228659784.USD","LU2125910500.SGD","SG9999002562.SGD","BK1598","IE00BQXX3C00.GBP","BK1188","01119","01520","IE00BPRC5H50.USD","06186","LU2506952253.HKD","02525","LU0588546209.SGD","BK1131","LU1046422090.SGD","SG9999001069.SGD","BK1200","BK1521","BK1126","BK1586","09880","BK1515","01651","BK1556","LU2177674079.SGD","LU2506951792.HKD","BK1132","BK1212","LU0320764599.SGD","02453","09955","02595","LU1328277881.USD","02509","LU2294711713.HKD","LU1770036033.HKD","LU1917777945.USD","SGXZ90724238.SGD","LU1115378108.SGD","BK1617","09877","SGXZ86797644.SGD","LU0048580855.USD","LU0289960550.SGD","LU0737861772.HKD","BK1179","LU1235295612.USD","BK1235","00960","BK1186","BK1605","BK1189","HK0000252152.HKD","BK1240","IE00B0JY6N72.USD","01378","LU0348766576.USD","IE00BGV7N243.SGD","IE00BVYPNQ40.USD","LU1242518931.SGD","LU2360107325.USD","LU0164939612.USD","02587","02886","IE00BVYPNP33.GBP","LU0823039010.USD","LU1497734951.SGD","SG9999002828.SGD","LU0054237671.USD","02145","BK1509","LU2097828557.USD","IE00BD6J9T35.USD","09956","LU2249611893.SGD","BK1541","LU0488056044.USD","01276","BK1183","LU0359201885.HKD","LU1807302812.USD","LU0051755006.USD","02096","BK1257","LU2488822045.USD","02197","BK1207","00017","LU0269904917.USD","BK1190","BK1548","LU0611395673.USD","LU0509642566.USD","LU1366334578.USD","02436","LU0640798160.USD","BK1128","BK1606","LU1675838814.USD","LU0164880469.USD","LU1993786604.SGD","LU2476274720.SGD","LU0149721374.USD","BK1613","LU2328871848.SGD","BK1516","LU0502904849.HKD","BK1215","09926","02590","SGXZ62798434.SGD","01177","BK1585","02171","LU0588545490.SGD","LU1634259391.SGD","IE00BMCWC346.EUR","LU2348773727.SGD","BK1221","SG9999015986.USD","SG9999001051.SGD","LU0593848301.USD","01117","BK1554","LU0128525689.USD","SG9999004311.SGD","LU1023057109.AUD","LU0979878070.USD","LU0072913022.USD","03836","01458","BK1615","LU1794554557.SGD","BK1214","SG9999002463.SGD","02331","LU1166156734.SGD","01585","IE00B8HQ1Z84.USD","01762","LU0251143458.SGD","LU0164865239.USD","BK1219","IE00BGHQDM52.EUR","BK1504","BK1583","LU2460026573.USD","HK0000320223.HKD","01530","00699","BK1109","BK1542","SG9999014674.SGD","IE00B29SXG58.USD","00003","IE00B543WZ88.USD","BK1239","LU2238339852.HKD","LU0229945570.USD","00382","LU0231483743.USD","09919","LU0823426308.USD","02256","LU0214875030.USD","LU1242518857.USD","00305","LU1226288170.HKD","02177","06996","LU0650527681.SGD","LU0823414478.USD","LU0048575426.USD","LU1770034418.SGD","BK1104","LU0572939691.SGD","06090","IE0031814852.USD","IE0008368742.USD","BK1237","LU0264606111.USD","LU0348784397.USD","09860","LU0708995583.HKD","LU1868837722.USD","LU2348774022.SGD","BK1524","SG9999004220.SGD","BK1593","BK1127","09639","02057","BK1163","BK1195","LU1497733631.SGD","00867","LU0449515922.USD","HK0000306701.USD"],"gpt_icon":1},{"id":"1197772551","title":"Fosun International (00656) Announces November 2025 Monthly Return With No Changes in Issued Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1197772551","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197772551?lang=en_us&edition=fundamental","pubTime":"2025-12-03 18:44","pubTimestamp":1764758668,"startTime":"0","endTime":"0","summary":"Fosun International Limited released its monthly return on movements in securities for the period ended 30 November 2025. The total number of issued ordinary shares remained at 8,166,635,624 with no...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656"],"gpt_icon":0},{"id":"2588788058","title":"Fosun Pharma Subsidiary Wins Acceptance for Drug Registration Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2588788058","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588788058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:44","pubTimestamp":1764679492,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Announces Acceptance of Subsidiary's Drug Registration Application. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7b6fkZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0060","BK0188","BK0183","BK0187","00656","BK1230","BK0028","BK0239","BK0175","BK0012","600196","BK0196"],"gpt_icon":0},{"id":"2588503712","title":"Shanghai Fosun Pharmaceutical Files Director List to HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2588503712","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588503712?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:41","pubTimestamp":1764675680,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL6lBVmQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","BK0012","BK0188","600196","BK0060","BK0096","BK0183","BK0028","BK0239","BK0187","BK0196","BK0175","00656"],"gpt_icon":0},{"id":"2588057126","title":"Fosun International (SEHK:656): Assessing Valuation as Recovery Momentum Builds","url":"https://stock-news.laohu8.com/highlight/detail?id=2588057126","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588057126?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:11","pubTimestamp":1764673901,"startTime":"0","endTime":"0","summary":"Fosun International (SEHK:656) sits at the intersection of multiple sectors, including health care, insurance, and intelligent manufacturing. This combination makes it an interesting company to keep an eye on as the market shifts.\nSee our latest analysis for Fosun International.\nFosun International’s share price has shown signs of regained momentum lately, with a 1-day return of 2.87% and a year-to-date price return of 13.61%. While the 1-year total shareholder return sits at a solid 17.29%,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/fosun-international-sehk656-assessing-valuation-as-recovery","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/fosun-international-sehk656-assessing-valuation-as-recovery","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2588034553","title":"Shanghai Henlius Biotech NDA for Denosumab Biosimilar Accepted by China NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2588034553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588034553?lang=en_us&edition=fundamental","pubTime":"2025-12-02 18:33","pubTimestamp":1764671606,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its New Drug Application  for HLX14, a biosimilar of denosumab , has been accepted for review by the National Medical Products Administration  of China. HLX14 is intended for all approved and marketed indications of the reference drug Prolia in mainland China, including the treatment of osteoporosis in postmenopausal women and men at high risk of fractures, as well as glucocorticoid-induced osteoporosis. The NDA submission was supported by analytical, nonclinical, and clinical comparison studies with Prolia. No grant or funding involvement from multiple organizations was mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL35tlSb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","HK0000165453.HKD","02696","BK1161","BK1230"],"gpt_icon":0},{"id":"1188533349","title":"Fosun International (00656) and Fosun Pharma (02196, 600196) Renew Mutual Supply Framework with CQ Pharma Holdings (000950)","url":"https://stock-news.laohu8.com/highlight/detail?id=1188533349","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188533349?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:46","pubTimestamp":1764333969,"startTime":"0","endTime":"0","summary":"Fosun International Limited (00656) announced that its subsidiary Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; 02196, 600196) entered into a renewed Mutual Supply Framework...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656"],"gpt_icon":0},{"id":"2586078446","title":"Fosun International Affiliate Fosun Pharma Expands Mutual Supply Agreement with CQ Pharma Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2586078446","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586078446?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:33","pubTimestamp":1764333237,"startTime":"0","endTime":"0","summary":"Fosun International Affiliate Fosun Pharma and CQ Pharma Holdings Extend Mutual Supply Framework Agreement. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on November 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL1zSMFB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000950","BK0012","BK0183","BK1230","600196","BK0187","00656","BK0028","BK0071","BK0250","BK0188","BK0096","BK0175","BK0196","BK0060","BK0239"],"gpt_icon":0},{"id":"1127150506","title":"FOSUN INTL (00656): Li Shupei Resigns as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1127150506","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127150506?lang=en_us&edition=fundamental","pubTime":"2025-11-27 17:40","pubTimestamp":1764236422,"startTime":"0","endTime":"0","summary":"FOSUN INTL (00656) announced that Mr. Li Shupei has resigned as the company's non-executive director due to personal work arrangements, effective from November 27, 2025.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosun.com","stockEarnings":[{"period":"1week","weight":-0.0142},{"period":"1month","weight":-0.0181},{"period":"3month","weight":-0.1486},{"period":"6month","weight":0.0564},{"period":"1year","weight":0.0384},{"period":"ytd","weight":0.0774}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Fosun International Ltd is a company principally engaged in the operation and investments in global consumer business. The Company operates its business through five segments. The Happiness segment engages in the operation and investments in tourism and leisure, fashion consumer and lifestyle industries. The Health segment engages in the research and development, manufacture, sale and trading of pharmaceutical and health products and providing medical services and health management. The Insurance segment mainly engages in the operation of and investment in the insurance businesses. The Asset Management segment comprises principally the operation and investment of asset management, market investments, and investments in other companies of the Group. The Intelligent Manufacturing segment comprises principally the operation of and investment in the intelligent manufacturing and iron, steel, new functional materials and ore production.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.007963},{"month":2,"riseRate":0.5,"avgChangeRate":0.01453},{"month":3,"riseRate":0.5,"avgChangeRate":-0.000408},{"month":4,"riseRate":0.555556,"avgChangeRate":0.034582},{"month":5,"riseRate":0.555556,"avgChangeRate":0.040571},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.012529},{"month":7,"riseRate":0.388889,"avgChangeRate":0.000713},{"month":8,"riseRate":0.105263,"avgChangeRate":-0.050815},{"month":9,"riseRate":0.578947,"avgChangeRate":-0.012339},{"month":10,"riseRate":0.421053,"avgChangeRate":-0.019588},{"month":11,"riseRate":0.473684,"avgChangeRate":0.019122},{"month":12,"riseRate":0.578947,"avgChangeRate":0.02589}],"exchange":"SEHK","name":"FOSUN INTL","nameEN":"FOSUN INTL"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest FOSUN INTL(00656) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"FOSUN INTL,00656,FOSUN INTL股票,FOSUN INTL股票老虎,FOSUN INTL股票老虎国际,FOSUN INTL行情,FOSUN INTL股票行情,FOSUN INTL股价,FOSUN INTL股市,FOSUN INTL股票价格,FOSUN INTL股票交易,FOSUN INTL股票购买,FOSUN INTL股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest FOSUN INTL(00656) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}